Peter Attia· MD
I think another big thing Nick that I spoke about and speculated about in the past was really around the changes in body composition and not just weight and I think I mentioned very specifically that in the phase three tiles the FDA did not require body composition as part of the primary outcomes so dexa scans were not um done in those studies and uh body weight was simply the metric of Interest and of course because we started doing dexa scans on people we were seeing some pretty different things with respect to body composition but the good news now is we can speak to that more from the standpoint of of the of the data that are available